vs
Side-by-side financial comparison of ACADIA REALTY TRUST (AKR) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $103.0M, roughly 1.9× ACADIA REALTY TRUST). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -1.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 7.0%).
Acadia Realty Trust is a publicly traded real estate investment trust (REIT) that specializes in owning, operating, and redeveloping high-quality retail and mixed-use properties, primarily in dense, high-barrier-to-entry U.S. markets. Its portfolio includes neighborhood shopping centers, urban street retail assets, and community-focused mixed-use developments.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AKR vs AXSM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $103.0M | $191.2M |
| Net Profit | $139.1M | — |
| Gross Margin | — | — |
| Operating Margin | 153.9% | -33.1% |
| Net Margin | 135.1% | — |
| Revenue YoY | -1.3% | 57.4% |
| Net Profit YoY | -58.2% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $103.0M | $191.2M | ||
| Q4 25 | — | $196.0M | ||
| Q3 25 | — | $171.0M | ||
| Q2 25 | — | $150.0M | ||
| Q1 25 | — | $121.5M | ||
| Q4 24 | $93.3M | $118.8M | ||
| Q3 24 | $87.7M | $104.8M | ||
| Q2 24 | $87.3M | $87.2M |
| Q1 26 | $139.1M | — | ||
| Q4 25 | — | $-28.6M | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-48.0M | ||
| Q1 25 | — | $-59.4M | ||
| Q4 24 | $1.2M | $-74.9M | ||
| Q3 24 | $12.3M | $-64.6M | ||
| Q2 24 | $1.6M | $-79.3M |
| Q1 26 | 153.9% | -33.1% | ||
| Q4 25 | — | -13.8% | ||
| Q3 25 | — | -27.0% | ||
| Q2 25 | — | -24.5% | ||
| Q1 25 | — | -46.9% | ||
| Q4 24 | 17.5% | -61.1% | ||
| Q3 24 | 19.9% | -59.8% | ||
| Q2 24 | 20.4% | -89.5% |
| Q1 26 | 135.1% | — | ||
| Q4 25 | — | -14.6% | ||
| Q3 25 | — | -27.6% | ||
| Q2 25 | — | -32.0% | ||
| Q1 25 | — | -48.9% | ||
| Q4 24 | 1.2% | -63.1% | ||
| Q3 24 | 14.0% | -61.7% | ||
| Q2 24 | 1.8% | -91.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.55 | ||
| Q3 25 | — | $-0.94 | ||
| Q2 25 | — | $-0.97 | ||
| Q1 25 | — | $-1.22 | ||
| Q4 24 | $0.08 | $-1.54 | ||
| Q3 24 | $0.07 | $-1.34 | ||
| Q2 24 | $0.01 | $-1.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.4M | $305.1M |
| Total DebtLower is stronger | — | $70.0M |
| Stockholders' EquityBook value | $2.6B | — |
| Total Assets | $4.5B | $713.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $31.4M | $305.1M | ||
| Q4 25 | — | $322.9M | ||
| Q3 25 | — | $325.3M | ||
| Q2 25 | — | $303.0M | ||
| Q1 25 | — | $300.9M | ||
| Q4 24 | $16.8M | $315.4M | ||
| Q3 24 | $46.2M | $327.3M | ||
| Q2 24 | $31.9M | $315.7M |
| Q1 26 | — | $70.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — |
| Q1 26 | $2.6B | — | ||
| Q4 25 | — | $88.3M | ||
| Q3 25 | — | $73.7M | ||
| Q2 25 | — | $73.1M | ||
| Q1 25 | — | $53.2M | ||
| Q4 24 | $2.1B | $57.0M | ||
| Q3 24 | $1.9B | $92.9M | ||
| Q2 24 | $1.8B | $102.9M |
| Q1 26 | $4.5B | $713.6M | ||
| Q4 25 | — | $689.8M | ||
| Q3 25 | — | $669.3M | ||
| Q2 25 | — | $639.8M | ||
| Q1 25 | — | $596.7M | ||
| Q4 24 | $4.4B | $568.5M | ||
| Q3 24 | $4.3B | $561.5M | ||
| Q2 24 | $4.3B | $548.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.95× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKR
| Rental | $98.6M | 96% |
| Other | $4.4M | 4% |
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
